Moderna (MRNA) has been in the limelight due to a series of crucial developments. Updated vaccines for COVID-19 from both Moderna and Pfizer/BioNTech have been approved by the FDA, greenlighting their use for the coming fall season. Both the vaccines have gained authorization to better protect against the current circulating variants of COVID-19. Government sources suggest that Moderna is set to receive $176 million to develop a novel mRNA bird flu vaccine, enhancing its stock price considerably. The company's pioneering efforts in creating mRNA vaccines for infectious diseases further solidify its innovative status. Moderna has also started a trial for a two-in-one flu and COVID-19 vaccine, showing promising findings. Additionally, they are working on a vaccine for Respiratory Syncytial Virus (RSV), which has won approval in the EU. Despite facing some legal hurdles, shareholders continue to exhibit faith in Moderna, with the stock rising 22% year-to-date. However, there have been some setbacks, such as the freeze of a Kenyan mRNA vaccine plant and a few puzzling side effects hindering the progress of an HIV vaccine development.
Moderna MRNA News Analytics from Mon, 27 Nov 2023 08:00:00 GMT to Sat, 24 Aug 2024 01:48:32 GMT -
Rating 8
- Innovation 9
- Information 8
- Rumor 7
